BACKGROUND: The association between vitamin D deficiency and obesity in healthy populations and different disease states remains unsettled with studies reporting conflicting findings. Moreover, current dietary recommendations for vitamin D do not take into account a person's body mass index (BMI). We investigated the relationship between serum 25-hydroxy-vitamin D [25(OH)D] and BMI in cancer. METHODS: A consecutive case series of 738 cancer patients. Serum 25(OH)D was measured at presentation to the hospital. The cohort was divided into 4 BMI groups (underweight: <18.5, normal weight: 18.5-24.9, overweight: 25-29.9, and obese: >30.0 kg/m²). Mean 25(OH)D was compared across the 4 BMI groups using ANOVA. Linear regression was used to quantify the relationship between BMI and 25(OH)D. RESULTS: 303 were males and 435 females. Mean age at diagnosis was 55.6 years. The mean BMI was 27.9 kg/m² and mean serum 25(OH)D was 21.9 ng/ml. Most common cancers were lung (134), breast (131), colorectal (97), pancreas (86) and prostate (45). Obese patients had significantly lower serum 25(OH)D levels (17.9 ng/ml) as compared to normal weight (24.6 ng/ml) and overweight (22.8 ng/ml) patients; p < 0.001. After adjusting for age, every 1 kg/m² increase in BMI was significantly associated with 0.42 ng/ml decline in serum 25(OH)D levels. CONCLUSIONS: Obese cancer patients (BMI ≥ 30 kg/m²) had significantly lower levels of serum 25(OH)D as compared to non-obese patients (BMI <30 kg/m²). BMI should be taken into account when assessing a patient's vitamin D status and more aggressive vitamin D supplementation should be considered in obese cancer patients.
BACKGROUND: The association between vitamin Ddeficiency and obesity in healthy populations and different disease states remains unsettled with studies reporting conflicting findings. Moreover, current dietary recommendations for vitamin D do not take into account a person's body mass index (BMI). We investigated the relationship between serum 25-hydroxy-vitamin D [25(OH)D] and BMI in cancer. METHODS: A consecutive case series of 738 cancerpatients. Serum 25(OH)D was measured at presentation to the hospital. The cohort was divided into 4 BMI groups (underweight: <18.5, normal weight: 18.5-24.9, overweight: 25-29.9, and obese: >30.0 kg/m²). Mean 25(OH)D was compared across the 4 BMI groups using ANOVA. Linear regression was used to quantify the relationship between BMI and 25(OH)D. RESULTS: 303 were males and 435 females. Mean age at diagnosis was 55.6 years. The mean BMI was 27.9 kg/m² and mean serum 25(OH)D was 21.9 ng/ml. Most common cancers were lung (134), breast (131), colorectal (97), pancreas (86) and prostate (45). Obesepatients had significantly lower serum 25(OH)D levels (17.9 ng/ml) as compared to normal weight (24.6 ng/ml) and overweight (22.8 ng/ml) patients; p < 0.001. After adjusting for age, every 1 kg/m² increase in BMI was significantly associated with 0.42 ng/ml decline in serum 25(OH)D levels. CONCLUSIONS:Obese cancerpatients (BMI ≥ 30 kg/m²) had significantly lower levels of serum 25(OH)D as compared to non-obesepatients (BMI <30 kg/m²). BMI should be taken into account when assessing a patient's vitamin D status and more aggressive vitamin D supplementation should be considered in obese cancerpatients.
Authors: Shanna Nesby-O'Dell; Kelley S Scanlon; Mary E Cogswell; Cathleen Gillespie; Bruce W Hollis; Anne C Looker; Chris Allen; Cindy Doughertly; Elaine W Gunter; Barbara A Bowman Journal: Am J Clin Nutr Date: 2002-07 Impact factor: 7.045
Authors: José I Botella-Carretero; Francisco Alvarez-Blasco; Juan J Villafruela; José A Balsa; Clotilde Vázquez; Héctor F Escobar-Morreale Journal: Clin Nutr Date: 2007-07-10 Impact factor: 7.324
Authors: Kendra A Young; Corinne D Engelman; Carl D Langefeld; Kristen G Hairston; Steven M Haffner; Michael Bryer-Ash; Jill M Norris Journal: J Clin Endocrinol Metab Date: 2009-06-23 Impact factor: 5.958
Authors: John F Payne; Robin Ray; David G Watson; Cecile Delille; Eva Rimler; Julia Cleveland; Michael J Lynn; Vin Tangpricha; Sunil K Srivastava Journal: Endocr Pract Date: 2012 Mar-Apr Impact factor: 3.443
Authors: Kathleen M Wesa; Neil H Segal; Angel M Cronin; Daniel D Sjoberg; Gria N Jacobs; Marci I Coleton; Martin Fleisher; Ann M Dnistrian; Leonard B Saltz; Barrie R Cassileth Journal: Nutr Cancer Date: 2015-02-03 Impact factor: 2.900
Authors: Charles B Eaton; Alicia Young; Matthew A Allison; Jennifer Robinson; Lisa W Martin; Lewis H Kuller; Karen C Johnson; J David Curb; Linda Van Horn; Anne McTiernan; Simin Liu; JoAnn E Manson Journal: Am J Clin Nutr Date: 2011-10-26 Impact factor: 7.045
Authors: Sarah K Holt; Suzanne Kolb; Rong Fu; Ronald Horst; Ziding Feng; Janet L Stanford Journal: Cancer Epidemiol Date: 2013-08-20 Impact factor: 2.984